ABSTRACT
BACKGROUND: Hamartoma is a common benign tumor that usually occurs in the kidney, liver, lung, and pancreas. Large renal hamartomas may spontaneously rupture and hemorrhage, which is potentially life-threatening. CASE PRESENTATION: This report describes a 46-year-old Han Chinese female patient with multiple renal and hepatic hamartomas with rupture and hemorrhage of giant hamartoma in the left kidney. She underwent arterial embolization three times successively, and her condition was stable during the 2-year follow-up. This report includes a review of the relevant literature CONCLUSIONS: the findings in this report and previous literature suggest that arterial embolization can not only rapidly treat hamartoma hemorrhage in the acute phase but can also effectively control multiple lesions in the long term after repeated multisite arterial embolization.
Subject(s)
Embolization, Therapeutic , Hamartoma , Humans , Female , Middle Aged , Hemorrhage/diagnostic imaging , Hemorrhage/etiology , Hemorrhage/therapy , Liver/diagnostic imaging , Hamartoma/complications , Hamartoma/diagnostic imaging , Hamartoma/therapy , Rupture , KidneyABSTRACT
El hamartoma fibrolipomatoso precalcáneo congénito (HFPC) es una entidad benigna e infrecuente caracterizada por la aparición, al nacimiento o meses después, de nódulos de tejido adiposo, simétricos y asintomáticos en las plantas de los pies. Cursa con una evolución favorable, con un crecimiento acorde a la edad del niño. El diagnóstico es clínico, aunque la ecografía podría ser de utilidad. Rara vez precisa pruebas complementarias agresivas o tratamiento alguno. Se presenta un caso clínico de un lactante que recibió dicho diagnóstico. (AU)
Precalcaneal congenital fibrolipomatous hamartoma is a benign and uncommon entity characterized by the appearance at birth or months later of nodules of adipose tissue, symmetrical and asymptomatic in the soles of the feet. It follows a favourable evolution, with a growth according to the age of the child. The diagnosis is clinical, although ultrasound may be helpful. Aggressive follow-up tests or treatment are rarely needed. We present a clinical case of an infant who received such a diagnosis. (AU)
Subject(s)
Humans , Male , Infant , Hamartoma/diagnosis , Hamartoma/therapy , Congenital Abnormalities , Heel/pathologyABSTRACT
Lipofibromatous hamartoma (LFH) is a rare fibrofatty tumor of adipocytes within peripheral nerves, affecting mainly children. It typically presents as a palpable mass surrounding the nerves of the upper limbs, causing pain and neurological deficits in the affected nerve distribution. We report the case of a child with a 2-years presentation of a mass in the right wrist associated with pain and paresthesia, who underwent investigation with magnetic resonance imaging (MRI). It showed thickening of the median nerve with spaghetti-like appearance associated with lipomatous tissue in a coaxial cable-like pattern, both features characteristic of LFH. This case illustrates the importance of MRI in the differential diagnosis of limb masses in the pediatric population.
Subject(s)
Humans , Child , Median Neuropathy/diagnostic imaging , Fibroma/diagnostic imaging , Hamartoma/diagnostic imaging , Median Neuropathy/therapy , Fibroma/therapy , Hamartoma/therapy , Lipoma/therapy , Lipoma/diagnostic imagingABSTRACT
Hypothalamic hamartomas (HH) are rare, basilar developmental lesions with widespread comorbidities often associated with refractory epilepsy and encephalopathy. Imaging advances allow for early, even prenatal, detection. Genetic studies suggest mutations in GLI3 and other patterning genes are involved in HH pathogenesis. About 50%-80% of children with HH have severe rage and aggression and a majority of patients exhibit externalizing disorders. Behavioral disruption and intellectual disability may predate epilepsy. Neuropsychological, sleep, and endocrine disorders are typical. The purpose of this article is to provide a summary of the current understanding of HH and to highlight opportunities for future research.
Subject(s)
Epilepsy , Hamartoma , Hypothalamic Diseases , Child , Comorbidity , Epilepsy/complications , Hamartoma/complications , Hamartoma/genetics , Hamartoma/therapy , Humans , Hypothalamic Diseases/complications , Hypothalamic Diseases/diagnosis , Hypothalamic Diseases/therapySubject(s)
Fluorescein Angiography/methods , Fovea Centralis/diagnostic imaging , Hamartoma/diagnosis , Retinal Diseases/diagnosis , Tomography, Optical Coherence/methods , Adult , Combined Modality Therapy/methods , Diagnosis, Differential , Female , Fundus Oculi , Hamartoma/congenital , Hamartoma/therapy , Humans , Retinal Diseases/congenital , Retinal Diseases/therapySubject(s)
Adenomatoid Tumor/diagnosis , Hamartoma/diagnosis , Nasopharyngeal Carcinoma/diagnosis , Nasopharyngeal Neoplasms/diagnosis , Paranasal Sinus Neoplasms/diagnosis , Adenomatoid Tumor/pathology , Adenomatoid Tumor/therapy , Aged , Diagnosis, Differential , Endoscopy , Female , Hamartoma/pathology , Hamartoma/therapy , Humans , Magnetic Resonance Imaging , Male , Medical Illustration , Nasal Mucosa/diagnostic imaging , Nasal Mucosa/pathology , Nasopharyngeal Carcinoma/pathology , Nasopharyngeal Carcinoma/therapy , Nasopharyngeal Neoplasms/pathology , Nasopharyngeal Neoplasms/therapy , Paranasal Sinus Neoplasms/pathology , Paranasal Sinus Neoplasms/therapy , Tomography, X-Ray ComputedABSTRACT
OBJECTIVES/HYPOTHESIS: To further clinically characterize lingual hamartomas, and to consolidate literature by analyzing clinical presentation, diagnostic evaluation, treatment, and outcomes. STUDY DESIGN: Retrospective chart review and literature review. METHODS: Case series from 1989 to 2020 at a tertiary pediatric center; follow-up ranging from 2 months to 12 years. Patient demographics, clinical presentations, physical examination findings, surgical pathology, operative methods, pre-operative imaging, and follow-up. A review of English-language literature from 1945 to 2020 was conducted. RESULTS: Seven patients (four male, three female) with nine lingual hamartomas were identified. Average age at surgical excision was 7.9 months (SD 3.5 months, range 3 to 14 months). Follow-up ranged from 2 months to 12 years, with all patients having no recurrence. Physical examination identified five pedunculated hamartomas and two sessile hamartomas. One patient had a neck CT, one had neck ultrasound, and two had facial MRIs. CT and ultrasounds confirmed presence of cervical thyroid. MRI suggested no muscular invasion for one patient, whereas motion artifact obscured findings for the other patient. Most patients who presented with dysphagia or poor weight gain achieved post-surgical improvement. The present cases combined with the literature review identified 57 patients with 63 lingual hamartomas. CONCLUSIONS: Lingual hamartomas appear as hypovascular pedunculated masses near the foramen cecum. There is no demographic predisposition, and most are identified during infancy. Imaging is not necessary, unless there is concern for lingual thyroid, in which case thyroid ultrasound should be performed. Surgical excision is curative, with dysphagia resolution and low likelihood for recurrence. LEVEL OF EVIDENCE: 4 Laryngoscope, 131:E2080-E2088, 2021.
Subject(s)
Hamartoma/diagnosis , Hamartoma/therapy , Tongue Neoplasms/diagnosis , Tongue Neoplasms/therapy , Diagnostic Imaging , Female , Humans , Infant , MaleABSTRACT
Benign liver tumors in children are far less frequent than their malignant counterparts. Recently, there have been advances of diagnostic procedures and novel treatments with improved classification as a result. While malignant pediatric liver tumors have been comprehensively addressed by multicenter international tumor trials, benign tumors have more usually relied upon individualised workup and treatment. Due to the rarity and heterogeneity of these different entities, large studies are lacking. In this article the authors highlight the spectrum of benign liver tumors with special focus on specific clinical features, pathology, and treatment.
Subject(s)
Adenoma/therapy , Focal Nodular Hyperplasia/therapy , Hamartoma/therapy , Hemangioma/therapy , Liver Neoplasms/therapy , Adenoma/pathology , Adenoma/physiopathology , Child , Focal Nodular Hyperplasia/pathology , Focal Nodular Hyperplasia/physiopathology , Hamartoma/pathology , Hamartoma/physiopathology , Hemangioma/pathology , Hemangioma/physiopathology , Humans , Liver Neoplasms/pathology , Liver Neoplasms/physiopathologyABSTRACT
Hypothalamic hamartomas (HH) are rare, non-neoplastic heterotopic tissues which contains normal neurons and glia including oligodendrocytes and fibrillary astrocytes but in an abnormal distribution. They arise from the floor of the third ventricle, tuber cinereum, or mammillary bodies. Estimated incidence ranges from 1 in 50,000 to 1 in 1,000,000. Hypothalamic hamartomas are associated with different clinical presentations including various types of seizures, most characteristically; the gelastic seizures, precocious puberty, cognitive impairment and behavioral changes. In this review, the authors discuss the recent advancements in the medical and surgical management of hypothalamic hamartoma that have been achieved over the past few decades. This review also discusses the advantages and disadvantages of each surgical line of management and factors determining the best individualized approach.
Subject(s)
Deep Brain Stimulation , Hamartoma/therapy , Hypothalamic Diseases/therapy , Neurosurgical Procedures , Vagus Nerve Stimulation , Hamartoma/surgery , Humans , Hypothalamic Diseases/surgery , Treatment OutcomeABSTRACT
Hamartoma is the most common benign pulmonary tumor in adults, but is rarely described in the pediatric population. Giant chondromatous and progressive forms are even rarer. We report the novel case of a 13-month-old infant hospitalized for giant pulmonary chondromatous hamartoma discovered during a septic episode, rapidly progressive, with severe multifocal lesions, without clear response to several cytotoxic therapies. No predisposition syndrome was identified.
Subject(s)
Hamartoma/pathology , Lung Diseases/pathology , Combined Modality Therapy , Female , Hamartoma/diagnostic imaging , Hamartoma/therapy , Humans , Infant , Lung Diseases/diagnostic imaging , Lung Diseases/therapy , Prognosis , Tomography, X-Ray Computed/methodsABSTRACT
INTRODUCTION: Clinical manifestations of the hypothalamic hamartoma-epilepsy syndrome (HH-ES) in adulthood are variable. Efficacy of therapeutic options and outcome are diverse. METHODS: Retrospective study of adult patients diagnosed with a HH in magnetic resonance imaging and epilepsy who attended our tertiary Epilepsy Unit between 2003 and 2018. We report the clinical and electroencephalographic features of a series of adult patients with HH and related epilepsy seen in our center together with the treatments and seizure outcome. RESULTS: We describe a series of eight patients. Five males (62.5%), median age at evaluation was 28.5 years (IQR: 15.5). Clinical manifestations included focal with preserved and impaired awareness emotional seizures (gelastic seizures [GS]) in six patients (75%), focal tonic, atonic with impaired awareness and focal to bilateral tonic-clonic seizures. Mild GS were the only symptom in one patient. Three patients (37.5%) had endocrinological disturbances such as obesity and hypothyroidism. Fifty percent of the patients showed psychiatric comorbidity such as anxiety disorder and aggressiveness, and two patients had psychomotor delay. Seven patients (87.7%) had drug-resistant seizures and three of them were treated with radiosurgery. Out of the treated group, only one (33.3%) became seizure-free 2 years after surgery but developed psychiatric problems. The other two patients had an Engel IV outcome and received a vagal nerve stimulation (VNS) implant. VNS did not lead to changes either in intensity nor in seizure frequency. CONCLUSIONS: Hypothalamic hamartoma-epilepsy syndrome clinical manifestations in adult patients are as variable as at pediatric age. Outcome of therapeutic options such as radiosurgery or VNS may be poorer at this stage.
Subject(s)
Drug Resistant Epilepsy/physiopathology , Epilepsies, Partial/physiopathology , Hamartoma/physiopathology , Hypothalamic Diseases/physiopathology , Adult , Aggression , Anticonvulsants/therapeutic use , Anxiety Disorders , Comorbidity , Drug Resistant Epilepsy/epidemiology , Drug Resistant Epilepsy/etiology , Drug Resistant Epilepsy/therapy , Electroencephalography , Epilepsies, Partial/epidemiology , Epilepsies, Partial/etiology , Epilepsies, Partial/therapy , Epilepsy , Female , Hamartoma/complications , Hamartoma/epidemiology , Hamartoma/therapy , Humans , Hypothalamic Diseases/complications , Hypothalamic Diseases/epidemiology , Hypothalamic Diseases/therapy , Hypothyroidism/epidemiology , Magnetic Resonance Imaging , Male , Middle Aged , Obesity/epidemiology , Psychomotor Disorders/epidemiology , Radiosurgery , Retrospective Studies , Seizures , Treatment Outcome , Vagus Nerve Stimulation , Young AdultABSTRACT
RATIONALE: Report a case of bilateral multiple retinal hamartomas (RAHs) in a patient with tuberous sclerosis complex (TSC) and introduced a new method (subthreshold micropulse laser photocoagulation) for the treatment of RAHs. PATIENT CONCERNS: A 20-year-old man with TSC complained of decreased vision and metamorphosia in both eyes for 2 months. At presentation, visual acuity (VA) was 20/32 in the right eye and 20/40 in the left eye. Fundus photographs, optical coherence tomography, fundus fluorescein angiography (FFA), and indocyanine green angiography indicated multiple RAHs in both eyes. DIAGNOSES: Bilateral retinal astrocytic hamartomas. INTERVENTIONS: In the right eye, 577ânm photocoagulation was adopted to treat the RAHs with obvious fluorescein leakage in FFA. The paramacular RAHs were treated by subthreshold micropulse mode to minimize the damage to macula. Photocoagulation therapy was administrated in the left eye after 1 dose of intravitreal ranibizumab treatment. OUTCOMES: After photocoagulation therapy (including subthreshold micropulse laser photocoagulation for the paramacular RAHs in both eyes), the VA improved to 20/25 OD and 20/32 OS with no recurrence of exudation. LESSONS: About 577ânm photocoagulation for the peripheral RAHs in combination with subthreshold micropulse laser photocoagulation for RAHs in the macular zone is a good option for multiple RAHs in patients with TSC.
Subject(s)
Hamartoma/therapy , Light Coagulation/standards , Retina/surgery , Tuberous Sclerosis/complications , China , Hamartoma/etiology , Humans , Lasers, Semiconductor/standards , Lasers, Semiconductor/therapeutic use , Light Coagulation/methods , Male , Retina/abnormalities , Retina/physiopathology , Retinal Diseases/etiology , Retinal Diseases/physiopathology , Tuberous Sclerosis/therapy , Young AdultABSTRACT
Although liver tumors are rare in the pediatric population, they are common in the setting of children with specific risk factors requiring increased awareness and, in some instances, screening. The evaluation of a liver mass in children is largely driven by the age at diagnosis, the presence of any medical comorbidities, and initial testing with alpha fetoprotein and imaging. Specific guidelines for the management of different tumors have been implemented in recent years such that a multidisciplinary approach is ideal and care should be provided by centers with experience in their management.
Subject(s)
Carcinoma, Hepatocellular/diagnosis , Carcinoma, Hepatocellular/therapy , Hepatoblastoma/epidemiology , Hepatoblastoma/therapy , Liver Neoplasms/diagnosis , Liver Neoplasms/therapy , Sarcoma/therapy , Adenoma/diagnosis , Adenoma/therapy , Adolescent , Carcinoma, Hepatocellular/epidemiology , Child , Child, Preschool , Diagnosis, Differential , Hamartoma/diagnosis , Hamartoma/therapy , Hemangioma/diagnosis , Hemangioma/therapy , Hepatoblastoma/diagnosis , Hepatoblastoma/pathology , Humans , Hyperplasia/diagnosis , Hyperplasia/therapy , Infant , Infant, Newborn , Liver Neoplasms/epidemiology , Liver Neoplasms/pathology , Liver Transplantation , Neoplasm Staging , Postoperative Care , Prognosis , Risk Assessment , Sarcoma/diagnosisABSTRACT
Tuberous sclerosis complex is a multisystemic, autosomal dominant genetic disorder with complete penetrance, that can evolve with hamartomas in multiple organs, such as skin, central nervous system, kidney and lung. Due to the wide phenotypic variability, the disease is often not recognized. Tuberous sclerosis complex affects one in 10,000 newborns and most patients are diagnosed during the first 15 months of life. The diagnostic criteria for tuberous sclerosis were reviewed in 2012, at the second International Tuberous Sclerosis Complex Consensus Conference. The diagnosis is based on genetic criteria, by the identification of inactivating pathogenic mutation of tumor suppressor genes TSC1 and TSC2, and clinical criteria, including cutaneous, renal, pulmonary, cardiac and neurological manifestations. The treatment of tuberous sclerosis complex consists, mainly, in management of the symptoms caused by hamartomas and in prevention of organ failure. Multidisciplinary approach is recommended, in order to obtain better clinical outcomes.
Subject(s)
Hamartoma/diagnosis , Tuberous Sclerosis/diagnosis , Hamartoma/genetics , Hamartoma/therapy , Humans , Immunosuppressive Agents/therapeutic use , Mutation , Sirolimus/therapeutic use , Tuberous Sclerosis/genetics , Tuberous Sclerosis/therapyABSTRACT
Abstract: Tuberous sclerosis complex is a multisystemic, autosomal dominant genetic disorder with complete penetrance, that can evolve with hamartomas in multiple organs, such as skin, central nervous system, kidney and lung. Due to the wide phenotypic variability, the disease is often not recognized. Tuberous sclerosis complex affects one in 10,000 newborns and most patients are diagnosed during the first 15 months of life. The diagnostic criteria for tuberous sclerosis were reviewed in 2012, at the second International Tuberous Sclerosis Complex Consensus Conference. The diagnosis is based on genetic criteria, by the identification of inactivating pathogenic mutation of tumor suppressor genes TSC1 and TSC2, and clinical criteria, including cutaneous, renal, pulmonary, cardiac and neurological manifestations. The treatment of tuberous sclerosis complex consists, mainly, in management of the symptoms caused by hamartomas and in prevention of organ failure. Multidisciplinary approach is recommended, in order to obtain better clinical outcomes.
Subject(s)
Humans , Tuberous Sclerosis/diagnosis , Hamartoma/diagnosis , Tuberous Sclerosis/genetics , Tuberous Sclerosis/therapy , Sirolimus/therapeutic use , Hamartoma/genetics , Hamartoma/therapy , Immunosuppressive Agents/therapeutic use , MutationABSTRACT
Las malformaciones glomuvenosas son hamartomas originados por la presencia de células glómicas en el músculo liso de las estructuras vasculares. Presentamos una serie de 13 casos de malformaciones glomuvenosas evaluadas clínicamente, estudiadas con ecotomografía Doppler color y confirmadas histológicamente. En las ecografías se observaron en todos los casos formaciones dérmicas e hipodérmicas superficiales, moderadamente delimitadas, de ecoestructura mixta, pseudonodulares, hipoecogénicas y heterogéneas con áreas tubulares y lacunares anecogénicas pseudoquísticas. El 85% de los casos demostró presencia de vasos arteriales y venosos, con predominio de los de baja velocidad (≤ 15 cm/s) sin shunts arteriovenosos. No se visualizó compromiso de estructuras profundas ni flebolitos. Los hallazgos clínicos y ecográficos podrían ayudar a precisar mejor el diagnóstico, la planificación quirúrgica o el seguimiento no invasivo en estas entidades
Glomuvenous malformations are hamartomatous lesions characterized by the presence of glomus cells in the vascular smooth muscle. We present the clinical and color Doppler ultrasound features of a series of 13 cases of histologically confirmed glomuvenous malformations. In all cases, the ultrasound study revealed moderately delimited superficial dermal and hypodermal pseudonodular structures of mixed echogenicity, with hypoechoic and heterogeneous areas and anechoic, pseudocystic tubular and lacunar zones. Arterial and venous vessels, mainly with a low flow (≤ 15 cm/s) were observed in 85% of patients, but no arteriovenous shunts were present. Deeper structures were not affected and no phleboliths were detected. The clinical and ultrasound findings could facilitate diagnosis, surgical planning, and noninvasive follow-up in these tumors
Subject(s)
Humans , Male , Female , Child , Adolescent , Young Adult , Adult , Middle Aged , Glomus Tumor/diagnostic imaging , Ultrasonography, Doppler, Color , Hamartoma/diagnostic imaging , Hamartoma/therapy , Vascular Neoplasms/diagnostic imaging , Immunohistochemistry/methods , Skin Diseases, Vascular/diagnostic imagingABSTRACT
No disponible
Subject(s)
Humans , Female , Aged , Hamartoma/diagnosis , Hamartoma/etiology , Hamartoma/therapy , Hamartoma/complications , Hamartoma/immunology , Hamartoma/pathologySubject(s)
Hamartoma/therapy , Hypothalamic Diseases/therapy , Neurosurgery/methods , Hamartoma/complications , Hamartoma/diagnosis , Hamartoma/history , History, 20th Century , History, 21st Century , Humans , Hypothalamic Diseases/complications , Hypothalamic Diseases/diagnosis , Hypothalamic Diseases/historyABSTRACT
The most common, and usually the only, endocrine disturbance in patients with hypothalamic hamartoma (HH) and epilepsy is central precocious puberty (CPP). The mechanism for CPP associated with HH may relate to ectopic generation and pulsatile release of gonadotropin-releasing hormone (GnRH) from the HH, but this remains an unproven hypothesis. Possible regulators of GnRH release that are intrinsic to HH tissue include the following: (1) glial factors (such as transforming growth factor α[TGFα) and (2) γ-aminobutyric acid (GABA)-mediated excitation. Both are known to be present in surgically-resected HH tissue, but are present in patients with and without a history of CPP, suggesting the possibility that symptoms related to HH are directly associated with the region of anatomic attachment of the HH to the hypothalamus, which determines functional network connections, rather than to differences in HH tissue expression or pathophysiology. CPP associated with HH presents with isosexual development prior to the age of 8 years in girls and 9 years in boys. It is not uncommon for CPP with HH to present in children at an earlier age in comparison to other causes of CPP, including in infancy. Surgical resection of the HH can be effective for treating CPP, but is reserved for patients with intractable epilepsy, since GnRH agonists are widely available and effective treatment. Other endocrine disturbances with HH are rare, but can include growth hormone deficiency, hypothyroidism, and adrenal insufficiency. Diabetes insipidus is commonly encountered postoperatively, but is not observed with HH prior to surgical intervention.
Subject(s)
Drug Resistant Epilepsy/physiopathology , Epilepsies, Partial/physiopathology , Hamartoma/physiopathology , Hypothalamic Diseases/physiopathology , Puberty, Precocious/physiopathology , Child , Child, Preschool , Comorbidity , Drug Resistant Epilepsy/diagnosis , Drug Resistant Epilepsy/therapy , Endocrine System Diseases/diagnosis , Endocrine System Diseases/physiopathology , Endocrine System Diseases/therapy , Epilepsies, Partial/diagnosis , Epilepsies, Partial/therapy , Female , Gonadotropin-Releasing Hormone/blood , Hamartoma/diagnosis , Hamartoma/therapy , Hormones, Ectopic/blood , Humans , Hypothalamic Diseases/diagnosis , Hypothalamic Diseases/therapy , Hypothalamus/physiopathology , Infant , Male , Nerve Net/physiopathology , Puberty, Precocious/diagnosis , Puberty, Precocious/therapy , Transforming Growth Factor alpha/physiology , gamma-Aminobutyric Acid/physiologyABSTRACT
BACKGROUND AND AIMS: Pulmonary hamartomas appear as parenchymal or endobronchial lesions, the latter representing '1.4 to 11%' of the total number of pulmonary hamartomas. Endobronchial hamartomas usually emerge as a single mass. As they are accepted as benign tumors, endobronchial treatments are recommended today. 45 year-old male patient admitted with cough, phlegm and fever. A lesion totally obstructing the right main bronchus was found in CT. METHODS: In his brochoscopy, a mobile, smooth-surfaced lesion obstructing right main bronchus was seen. Its histopathology was reported as 'hamartoma.' RESULTS: The lesion was removed by using argon plasma coagulation and electrocotery. After the removal of the lesion in right main bronchus, another lesion with similar characteristics was seen in the intermedius bronchus and this lesion which histopathology was reported as 'hamartoma' was excised by using electrocauter snare. There was no recurrence in the 24 month follow-up. CONCLUSION: Reports of multiple endobronchial hamartomas are rare in the literature, and the awareness of this form of benign disease is important in the differential diagnosis of pulmonary diseases.